Stifel lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $445 from $455 and keeps a Hold rating on the shares. The commercial business appears to have a more narrow variance on a quarter-to-quarter basis, making Vertex “less of a beat-and-raise story and more one that may be dependent on pipeline for significant upside,” the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Buy Rating Amid Promising Growth and Strategic Expansion
- Vertex Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Signals
- Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays
- Vertex Pharmaceuticals Reports Strong Q3 2025 Results
- Closing Bell Movers: Palantir down 3% after earnings